A Prospective Study of Sentinel Lymph Node Mapping for Endometrial Cancer: Is It Effective in High-Risk Subtypes?
Lei YeShuangDi LiWen LuQiZhi HeYiRan LiBiLan LiXiaoJun WangQin YanXiaoping WanPublished in: The oncologist (2019)
The efficacy of sentinel lymph node (SLN) mapping for high-risk endometrial cancer remains unclear. This study enrolled 131 patients with early-stage endometrial cancer who underwent cervical injection of indocyanine green SLN mapping followed by systematic pelvic lymphadenectomy and para-aortic lymphadenectomy. The key result was that SLN mapping yielded a low sensitivity and a high false-negative rate for the identification of node metastasis in endometrial cancer with high-risk histologies. The SLN strategy in these patients may increase the risk of missed diagnosis of isolated para-aortic node metastases and seems to be unacceptable in clinical practice.
Keyphrases
- endometrial cancer
- sentinel lymph node
- early stage
- lymph node
- high resolution
- neoadjuvant chemotherapy
- high density
- clinical practice
- end stage renal disease
- aortic valve
- ejection fraction
- newly diagnosed
- pulmonary artery
- chronic kidney disease
- left ventricular
- prognostic factors
- heart failure
- coronary artery
- peritoneal dialysis
- squamous cell carcinoma
- ultrasound guided
- radiation therapy